DANA-FARBER CANCER INSTITUTE

Hoth Therapeutics receives IRB approval from Dana-Farber Cancer Institute and Montefiore Medical Center for Phase 2a clinical trial of HT-001 to treat skin toxicities from EGFRi, with $9 million in cash and no plans for further capital raise in 2024.

A phase 1b study of abemaciclib monotherapy in heavily pretreated patients with metastatic ccRCC showed no clinically meaningful activity, with no objective responses and rapid disease progression in most patients. Despite the negative results, these findings are crucial for understanding the potential of CDK4/6 inhibitors in combination therapies for RCC, guiding future trials.